Podcasts about Second line

In this week's episode, joined by 2024 New Orleans-Matsue Sister City Exchange Program participants Katherine Heller & Wade Trosclair, the Krewe looks back & celebrates 30 years of friendship between Matsue, Japan & New Orleans, Louisiana... a sister city relationship built on cultural exchange, mutual curiosity, &shared spirit. Together, they reflect on their time in Matsue during the exchange program, their experiences with host families, and the deep connections that form when two communities separated by an ocean come together.------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode (timestamps [hh:mm:ss] where you can find the code)!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan!  (00:53:00)------ Past Matsue/Sister City Episodes ------Lafcadio Hearn: 2024 King of Carnival (S5Bonus)Explore Matsue ft. Nicholas McCullough (S4E19)Jokichi Takamine: The Earliest Bridge Between New Orleans & Japan ft. Stephen Lyman (S4E13)The Life & Legacy of Lafcadio Hearn ft. Bon & Shoko Koizumi (S1E9)Matsue & New Orleans: Sister Cities ft. Dr. Samantha Perez (S1E2)------ Links about the Exchange ------2024 Exchange Program Info/PicturesShogun Martial Arts Dojo (Katie's family's dojo)------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

Al Maginnes has published 15 books of poetry, including Fellow Survivors: New and Selected Poems (Redhawk Publications, 2023) and most recently Second Line, a sonnet sequence which just released this month. He has worked as a mail clerk, a landscaper, an electrician, a carpenter's helper, a hammock weaver, surveyor, and, since 1990, as a teacher. Al has published widely, including issues 63 and 89 of Rattle. He lives with his family in Raleigh, NC. Find his new and selected here: https://redhawkpublications.com/Fellow-Survivors-p529556536 As always, we'll also include the live Prompt Lines for responses to our weekly prompt. A Zoom link will be provided in the chat window during the show before that segment begins. For links to all the past episodes, visit: https://www.rattle.com/page/rattlecast/ This Week's Prompt: Write a haiku sequence inspired by the seasons. Next Week's Prompt: Write a poem about the influence music has had on you over the years while making the poem itself as musical as possible. The Rattlecast livestreams on YouTube, Facebook, and Twitter, then becomes an audio podcast. Find it on iTunes, Spotify, or anywhere else you get your podcasts.

The Krewe sits down with Haruka Kikuchi, a Japanese jazz trombonist making waves in New Orleans. From discovering jazz in Japan to second-lining through the Crescent City, Haruka shares her story of finding home through music — and how jazz bridges cultures across oceans.  ------ About the Krewe ------The Krewe of Japan Podcast is a weekly episodic podcast sponsored by the Japan Society of New Orleans. Check them out every Friday afternoon around noon CST on Apple, Google, Spotify, Amazon, Stitcher, or wherever you get your podcasts.  Want to share your experiences with the Krewe? Or perhaps you have ideas for episodes, feedback, comments, or questions? Let the Krewe know by e-mail at kreweofjapanpodcast@gmail.com or on social media (Twitter: @kreweofjapan, Instagram: @kreweofjapanpodcast, Facebook: Krewe of Japan Podcast Page, TikTok: @kreweofjapanpodcast, LinkedIn: Krewe of Japan LinkedIn Page, Blue Sky Social: @kreweofjapan.bsky.social, & the Krewe of Japan Youtube Channel). Until next time, enjoy!------ Support the Krewe! Offer Links for Affiliates ------Use the referral links below & our promo code from the episode (timestamps [hh:mm:ss] where you can find the code)!Support your favorite NFL Team AND podcast! Shop NFLShop to gear up for football season!Zencastr Offer Link - Use my special link to save 30% off your 1st month of any Zencastr paid plan!  (00:53:00)------ Past Music Episodes ------S5E13 - The Thunderous Sounds of Taiko ft. Takumi Kato (加藤 拓三), World Champion Taiko DrummerS5E10 - The Japanese Pop Music Scene ft. Patrick St. MichelS4E1 - Shamisen: Musical Sounds of Traditional Japan ft. Norm Nakamura of Tokyo LensS3E14 - City Pop & Yu ft. Yu HayamiS3E1 - Exploring Enka ft. Jerome White Jr aka ジェロ / Jero------ Links about Haruka ------Haruka's Website Haruka on IGHaruka on FacebookHaruka on YouTubeGoFundMe to Help Support Haruka's Family------ JSNO Upcoming Events ------JSNO Event CalendarJoin JSNO Today!

From 'The Skate Podcast' (subscribe here): Is Zacha going to be 2nd line center? And other potential shake ups to the Bruins line projections. Lysell among young players who stood out. Is Geekie about to have another career year? To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Ep 479, pt 2: Is Zacha going to be 2nd line center? And other potential shake ups to the Bruins line projections. Lysell among young players who stood out. Is Geekie about to have another career year? To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Drs. Liu and Scott review second-line treatments of small cell lung cancer following first-line maintenance treatment, including platinum rechallenge and other post-platinum agents.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Samuel Yamshon, MD The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategies in combination with chemoimmunotherapy—they raise important questions around sequencing, durability, and patient selection. Joining Dr. Charles Turck to explore the real-world implications of this evolving approach is Dr. Samuel Yamshon, Director of the Cellular Therapy Service and an Assistant Professor of Medicine at Weill Cornell Medicine in New York.

0:30- Intro 2:30- Second Line 7:41- Jordan Hawkins X Factor 20:00- Who Will Play The Most Off The Bench? 24:00- Strengths and Weaknesses Of Bench 32:20- Best Defender On Bench 45:00- Generational Talent 53:00- SKC Update    

Tune in for '20 Years after Katrina: New Orleans Second Line Music Before and After the Storm: Field Recordings and Interview with Musicologist Nelson Eubanks' hosted with Jacob.ABOUT NELSON EUBANKSBorn in New York City, Nelson Eubanks grew up in New York and New Jersey. He received a B.A. from Columbia University in 1994, an M.A. in creative writing from the university of San Francisco in 1998 and an MFA in creative writing from Columbia University in 2003. Eubanks published his first book 'The First Thing Smoking' in 2003, he is a 2023 recipient of the Jazz Road Creative Residencies Grant and founder of Melodius Thunk Productions.Melodious Thunk began before Hurricane Katrina as a community project in the Crescent City by a small group of New Orleans artists hoping to record the Sunday 2nd Line Parades. Over the years we've grown as we've ventured round the world into other sonic communities filled with like minded folks enamored by the exhilarating sounds of music in the street. We go out and find the music alive in its element in the streets of the musician's homes where folks feel comfortable enough to do what they wanna, let go, sing along, have a time. Then we ask the musicians about their sound so they can tell us in their own words what makes their rhythms so magnificent. Our mission is to be a bridge between the music of the street and your eyes and ears by fully documenting both rising artists and master musicians playing authentic, unfiltered rhythms in juke joints, at music festivals, in their homes, their corners, their bars, on their porches and then too, the very much under-documented great moving parades and processions of our time.This CREATIVES interview with Nelson Eubanks hosted with Jacob aired onWednesday September 3 at 5pm. Tune in at 88.1 Ithaca, 89.7 Southern Finger Lakes, or stream from anywhere at WRFI.org/listen

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Welcome back to Model Citizens: AI Compliance for Banks and Fintech Lenders, a six-part miniseries from the Fintech Takes podcast in partnership with FairPlay.  With FairPlay's Kareem Saleh (Founder & CEO) at my side, we unpack: how can banks and fintechs build fair, compliant lending systems in a time of regulatory uncertainty? In episode 3, we're digging into compliance in the age of AI; an area that isn't always top of mind for builders in fintech, but absolutely should be. Both of our guests today —  Chelsea Keegan (Chief Compliance Officer at Flex) and Eli Corbett (VP, Deputy General Counsel at Affirm) —  have built compliance functions inside high-growth fintech companies, either in their current roles or in the past.  So we're taking this opportunity to learn from their experience (what they've seen, what they've learned, and how they've approached compliance). Together, we unpack the new realities of legal risk in fintech … and why compliance can't just be a legal function anymore Highlights include: How you can't compliance your way out of a bad product (why product, engineering, and legal need to be in the room together, especially when building with AI) Regulators are watching your blog posts. Your marketing language might be Exhibit A in a future consent order Why nimble tech, cultural fluency, and strong governance matter more than legacy checklists or canned audits Why a fintech's worst-case scenario isn't the same as a bank's (and both sides need to plan accordingly) Don't forget to subscribe and catch the rest of Model Citizens; we're just getting started! This miniseries is brought to you by FairPlay. FairPlay is an AI enablement company for financial services. They help companies build, test, optimize, validate and govern AI models. Learn more at Fairplay.ai Sign up for Alex's Fintech Takes newsletter for the latest insightful analysis on fintech trends, along with a heaping pile of pop culture references and copious footnotes. Every Monday and Thursday: https://workweek.com/brand/fintech-takes/ And for more exclusive insider content, don't forget to check out my YouTube page. Follow Alex:  YouTube: https://www.youtube.com/channel/UCJgfH47QEwbQmkQlz1V9rQA/videos LinkedIn: https://www.linkedin.com/in/alexhjohnson Twitter: https://www.twitter.com/AlexH_Johnson Follow Kareem: https://www.linkedin.com/in/kareemsaleh/ Follow Chelsea: LinkedIn: https://www.linkedin.com/in/chelsea-keegan/ Follow Eli:LinkedIn: https://www.linkedin.com/in/elizabeth-eli-corbett-1b0177130/

Moses Patrou has spent the past twenty-five years in New York, carving out a unique space as a multi-instrumentalist and bandleader. From early days in Madison, Wisconsin playing hand drums in hip hop bands, to immersing himself in Cuban and Brazilian traditions, to gigging across the city in every imaginable context, Patrou has done it all. During the pandemic, he taught himself to play organ—a transformation that has reshaped his sound and his role in the scene. Here he reflects on the long road behind his new record Confession of a Fool - a soulful and striking record that represents the culmination of a lifetime in music - and what it means to make a defining statement at midlife. Patrou talks about the house fire that nearly took everything, the influence of his father (a piano player who named him after Mose Allison), and the difference between being a sideman and stepping into the spotlight. “There's a certain point where the music has to come through your experience,” he says. “It has to filter through your life.” Today, on the ocassion of the 300th episode of The Third Story, there is no better person to talk to than Moses Patrou. www.third-story.comwww.leosidran.substack.com www.wbgo.org/podcast/the-third-story

Host Charlie Beetson is joined by Sabina Ausfelt (Head of Regulatory, Risk & Oversight | MLRO, Juni), Teresa Conde Karpe (Senior Financial Crime Prevention Officer, Lunar), Jens Kihlgren-Månsson (Compliance Officer Nordics, Aion Bank), and Joakim Molinder (Subject Matter Expert, FCP Development, Handelsbanken) to explore the role of RegTech in combating financial crime. This discussion highlights evolving approaches to anti-money laundering, second line of defence strategies, and how Nordic institutions are using compliance technology to stay ahead in risk management.

Chef Kelly English joins Holly Whitfield on this week's Sound Bites to talk about the Second Line's renovations, their Hawaiian pop-up and a surprise celebrity visit to Restaurant Iris. English offers plenty of Memphis food recommendations and several hot takes on crime, Kroger and more.

This is a free preview of a paid episode. To hear more, visit www.basuandgodin.comOn this episode of the Basu & Godin Notebook ⬇️ ➡️ Let's go crazy first with Crosby (0:00)➡️ John Tavares (29:45)➡️ Sam Bennett (35:30)➡️ Bo Horvat (45:20) ➡️ William Karlsson (1:00:30)➡️ Ryan O'Reilly (1:05:00)➡️ Youngish RFA's: Geekie, McTavish, McLeod (1:09:00)➡️ Monday Mailbag (1:27:00)#hockey #canadiensmtl #basuandgodin #thenotebook #habs #podcast …

We discuss the recent media availability of the Ottawa Senators' management following the end of the season. Not a ton of information was shared during the press conference, particularly regarding player contracts and future plans. The conversation shifts to Claude Giroux's future with the team and the potential challenges in contract negotiations. We also delve into Shane Pinto's desire for more power-play time and the potential competition between Pinto and Dylan Cozens for the second-line center position next season. We talk about the Joel Quenneville hiring in Anaheim, and we have some strong thoughts on Utah's Mammoth decision on a new name and logo.

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unresponsive to first‑line b/tsDMARDs.

Nick Kypreos, Justin Bourne and Sam McKee look back on the Leafs' 7-2 beat down over the Philadelphia Flyers on Tuesday. They get into the inspiring recent play of John Tavares and the second line, what the Leafs' ideal bottom six would look like, Nick Robertson's chances at starting Game 1 in the playoffs, William Nylander hitting the 40-goal mark and much more. Then, they weigh in on the Flyers' future and head coach John Tortorella's frustrated post-game comments. Finally, they go to McKee's Midweek Mailbag to answer your questions!The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliate.

CME credits: 0.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/ When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need! =

Jesse Montano and Meghan Angley break down Jonathan Drouin's sharp scouting in the shootout, knowing Brock Nelson's move would beat Montembeault in Montreal. They take a closer look at Gabriel Landeskog's leadership style and his impact as captain, plus assess the Avs' Canadian road trip. Sam Malinski shares his thoughts on coming out of the 4 Nations break refreshed and stepping into a bigger role. Plus, updates from Jared Bednar and a deep dive into Colorado's evolving second line with Nelson, Necas, and Lehkonen. Get your fix on all things hockey with Off Ice!

Editor's Summary by JAMA Deputy Editors Linda Brubaker, MD, and Preeti Malani, MD, MSJ, for articles published from March 15-21, 2025.

The fellas are back with the second Oil Stream of the week, and like usual, lots to discuss. The fellas will hash out their thoughts from the Oilers' previous performance against the Sabres... they'll also be looking ahead to tomorrow's matchup against the New Jersey Devils. Who'll be in the lineup, who'll be in the net? All that will be discussed and so much more on today's edition of The Oil Stream! The Oil Stream is presented by Boston Pizza!

Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002045. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/37700494/ Fibrosis-4 (FIB-4) Calculator https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 Liver Fibrosis Assessment: MR and US Elastography https://pubmed.ncbi.nlm.nih.gov/34687329/ Using the FIB-4, Automatically Calculated, Followed by the ELF Test in Second Line to Screen Primary Care Patients for Liver Disease https://pubmed.ncbi.nlm.nih.gov/38806580/ American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) https://pubmed.ncbi.nlm.nih.gov/35569886/ Mediterranean Diet and Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/29785077/ Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction https://pubmed.ncbi.nlm.nih.gov/39470028/ Current Status of Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/39801787/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Update on the Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/35110946/

CME credits: 1.00 Valid until: 06-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/sequencing-strategies-for-second-line-and-beyond-treatment-of-her2-mbc/29947/ The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 06-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/leveraging-clinical-data-her2-targeted-adcs-in-second-line-and-beyond-mbc/29946/ The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 06-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-tki-combinations-in-second-line-and-beyond-mbc/29945/ The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.00.

A six goal game powered by the Avalanche second line with 2 goals from Lehkonen, 1 from Drouin and one from Mittelstadt add on to a couple from Makar as the Avs run away with this one Intro - 0:00Biggest takeaway? - 1:15Happy with the first line? - 7:06A little nit pick - 11:22Gotta talk about Cale - 12:18Third Star - 18:19Second Star -  20:50First Star - 24:10Let's hear from Bednar - 32:30Manimal - 45:40Superchats - 50:20Wrapping up - 52:25 An ALLCITY Network Production PARTY WITH US: https://thednvr.com/events   ALL THINGS DNVR: https://linktr.ee/dnvrsports MERCH: https://store.allcitynetwork.com/collections/dnvr-locker SUBSCRIBE: https://www.youtube.com/c/DNVR_Sports Breck Brew Ice Deck Giveaway: http://breckbrew.com/icedeck  bet365: Go to https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLER    Empire Today: Schedule a free in-home estimate today! All listeners can receive a $350 OFF discount when they use the promo code DNVR. Restrictions apply. See https://empiretoday.com/dnvr for details Coach Prime wants to help you and other Coloradans be your healthiest selves as the Chief Motivation Officer of UCHealth's Ready. Set. CO challenge. If you want to join the challenge, go to https://www.uchealth.org/readysetco Get Coors Light delivered straight to your door with Instacart by going to https://coorslight.com/DNVR. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado.    Rugged Road: Gear up for your next adventure with Rugged Road Coolers - Your ultimate outdoor companion! Head to http://ruggedroadoutdoors.pxf.io/ALLCITY and use code DNVR for 10% off!  Download the Circle K app and join the Inner Circle or visit https://www.circlek.com/inner-circle!   Download the Gametime app, create an account, and use code DNVR for $20 off your first purchase. Terms apply. Check out FOCO merch and collectibles here https://foco.vegb.net/DNVR and use promo code “DNVR10” for 10% off your order on all non Pre Order items. Exclusively for our listeners, Shady Rays is giving out their best deal of the season. Head to https://shadyrays.com and use code: DNVR for 35% off polarized sunglasses. Try for yourself the shades rated 5 stars by over 300,000 people. This episode is brought to you by BetterHelp. Give online therapy a try athttps://betterhelp.com/dnvr today to get 10% off your first month and get on your way to being your best self. Get 10 FREE meals at https://hellofresh.com/freeavalanche. Applied across 7 boxes, new subscribers only, varies by plan. https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLER   When you shop through links in the description, we may earn affiliate commissions.   Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.#coloradoavalanche #hockey #hockeypodcast

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it's important to identify biomarkers that can predict a patient's response to therapy. That's why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial's findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-guideline-recommendations-for-biomarker-based-second-line-treatment-of-mcrc/29851/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarker-driven-therapies-in-the-second-line-treatment-of-advanced-gastricgej-cancers-what-do-the-data-say/29847/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-her2-directed-therapy-for-second-line-treatment-of-her2-metastatic-breast-cancer/29828/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations. Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-second-line-treatment-following-an-immune-checkpoint-inhibitor-in-renal-cell-carcinoma/29199/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

PLAYLIST: Pacific St Blues & Americana                     December 15, 2024Support our Show and get the word out by wearin' our gear NOW in our 34th Year!Contact Us for more Information All New - Spotlight Shows podcast page1. Lightin' Hopkins / Santa2. John Lee Hooker / Blues for Christmas 3. Charles Brown / Christmas in Heaven4. Johnny Adams / The Little Boy That Santa Forgot 5. Johnny Winter w/ Edgar Winter / Please Come Home for Christmas6. Swampboy / Poor Man's Christmas 7. WC Clark / Party 8. Coco Montoya / A Bluesman Christmas9. Sheryl Crow & Eric Clapton / Merry Christmas Baby 10. Little Steven & the Disciples of Soul / Merry Christmas (I don't wanna fight tonight) 11. Kermit Ruffin / A Saints Christmas12. Putumayo Christmas / Santa's Second Line 13. Joanne Shaw Taylor / Hold of My Heart14. Beth Hart / Drunk on Valentine 15. Ronnie Baker Brooks / Accept My Love 16. Marcus King / Soul It Screams17. Gregg Allman / These Days18. Bonnie Raitt / Everywhere I Go19. Dave Alvin / Redneck Friend20. Keb Mo / Rock Me on the Water

Tommy talks to Rafael Goyeneche, President of the Metropolitan Crime Commission

Last Chance to Grab CONTENT BY DESIGN at 2024 Pricing!How to Market as a 2nd Line | 5th Line Profile in Human DesignEver feel like you're playing small in your business—or struggling to show up as your authentic self? In this episode of Unjaded, Vickie Dickson unpacks the power of your Human Design profile and how it can transform the way you approach your business. From overcoming the conditioning tied to your innate design to learning how to "do it scared," Vickie provides actionable insights that will inspire you to embrace who you're meant to be and share your unique gifts with the world. If you're ready to unlock your true potential and build a business aligned with your authentic self, this episode is for you.Before we get started… I love hearing from you!

13 people were shot at the annual Nine Times second line in St Roch on Sunday, and now we're having a new round of conversations about gun control, violence in the culture and more

The Sabres are getting scary play from their second line and it isn't scary good either. We talk about the struggles of Dylan Cozens and Jack Quinn and Buffalo's limited options to solve the issue. We also talk about the performance of Buffalo's goaltenders and how a bit more consistency from the pair could pay dividends through a friendly upcoming schedule. The show kicks off with a conversation about the recent Sportico team valuations and the Sabres 26% increase to a reported $1.13 billion. 

This is Chicago Hockey Radio, brought to you by the Alithio Network, with your hosts Justin Lynch, Lee Grasemann, and Tassos Kirkos! The place to be for everything Blackhawks Hockey. DM @chicagohockeyradio on Instagram to have your questions read on Fridays Subscribe to our YouTube channel: https://www.youtube.com/@ChicagoHockeyRadio

The JournalFeed podcast for the week of Oct 7-11, 2024.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Tuesday Spoon Feed:ACEP released a clinical policy that addresses the choice of a second-line agent for adults with refractory seizures after adequate dosing of benzodiazepines.Friday Spoon Feed:Cavernous sinus thrombosis (CST) is a rare but serious thrombophlebitic disease that can be easy to miss in the emergency department setting. This article provides an overview of CST as well as some pearls for clinching this diagnosis for emergency medicine physicians.

On to the second line and defensive pair! Breaking down our projections and predictions for what we and most Ranger fans hope will be the 5 men on the ice for the majority of the season!

On to the second line and defensive pair! Breaking down our projections and predictions for what we and most Ranger fans hope will be the 5 men on the ice for the majority of the season! Learn more about your ad choices. Visit megaphone.fm/adchoices

In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.

In this curated episode of the Revenue Builders Podcast, John McMahon and John Kaplan are joined by Carl Cross, the CRO of Alchemy Technology, to delve into the complexities of second line leadership. The discussion centers around the critical skills required to train and lead first line leaders, the common pitfalls second line managers face, and strategies to ensure that leadership at every level is effective and empowering. This episode offers valuable insights for those looking to elevate their leadership capabilities and drive better results through their teams.KEY TAKEAWAYS[00:00:49] Defining a Great First Line Leader[00:01:42] Common Mistakes of Second Line Leaders[00:02:28] Transitioning from Tactical to Strategic Thinking[00:04:14] Balancing Field Connection with Leadership Responsibilities[00:06:24] Segregation of Duties Between First and Second Line ManagersHIGHLIGHT QUOTES[00:00:49] "You're obviously driving results through leaders, right? And there's something different about that."[00:01:42] "The mistake that I see a lot of second line make is... you rip the steering wheel out of their hands."[00:02:28] "The further you move up the range, the lonelier it gets at the top."[00:05:12] "It's their ultimate responsibility that every person on that team has an equal chance of success."[00:06:24] "You have to actually outline segregation of duties between first line manager and second line manager."Listen to the full episode with Carl Cross through this link: https://revenue-builders.simplecast.com/episodes/the-path-to-sales-leadership-lessons-learned-at-each-management-level-with-carl-crossCheck out John McMahon's book here:Amazon Link: https://a.co/d/1K7DDC4Check out Force Management's Ascender platform here:https://my.ascender.co/Ascender/Read Force Management's eBook: https://www.forcemanagement.com/front-line-managers 

TSN Maple Leafs Reporter Mark Masters joins OverDrive to discuss Bobby McMann landing a two-year extension earlier this afternoon. Masters shares his thoughts on why McMann's extension represents a feel-good story for the franchise, what type of timeline Mitch Marner might be looking at as he continues his recovery from a mysterious injury, why he expects John Tavares to be centering the second line when the playoffs begin for the Leafs, and more.